The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mercadel, Lucile ^a,b   Metzger, Marie ^a,c   Haymann, Jean Philippe ^d   Thervet, Eric ^e   Boffa, Jean Jacques ^f   Flamant, Martin ^g,h   Vrtovsnik, François ^g,h   Houillier, Pascal ^e   Froissart, Marc ^a   Stengel, Bénédicte ^a,c  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL TENON   (France)

^g BICHAT HOSPITAL   (France)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; EDETATE CHROMIUM CR 51; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; TRANSFERRIN; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; IRON DEFICIENCY; IRON METABOLISM DISORDER; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; AGED; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; IRON DEFICIENCY ANEMIA; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; FEMALE; HEMOGLOBINS; HEPCIDINS; HUMANS; INFLAMMATION; IRON; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84903609037     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099781     Document Type: Article

References (30)

1. Ulukol B, Orhon FS, Hanoluk A, Akar N (2007) Serum pro-hepcidin levels and relationship with ferritin in healthy individuals non-anaemic infants. Acta Haematol 118(2): 70-2.
2. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, et al. (2008) Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 28(1): 115-121.
3. Malyszko J, Malyszko JS, Mysliwiec M (2009) A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. Transplant Proc 41(8): 3056-9.
4. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, et al. (2006) Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108(4): 1381-7.
5. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, et al. (2009) Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113(21): 5277-86.
6. Grebenchtchikov N, Geurts-Moespot AJ, Kroot JJ, den Heijer M, Tjalsma H, et al. (2009) High-sensitive radioimmunoassay for human serum hepcidin. Br J Haematol 146(3): 317-25.
7. Li H, Rose MJ, Tran L, Zhang J, Miranda LP, et al (2009) Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods 59(3): 171-80.
8. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, et al. (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75(9): 976-81.
9. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, et al. (2010) Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5(6): 1010-4.
10. Malyszko J, Malyszko JS, Mysliwiec M (2009) Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren Fail 31(7): 544-8.
11. Costa E, Swinkels DW, Laarakkers CM, Rocha-Pereira P, Rocha S, et al. (2009) Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 122(4): 226-9.
12. Ford BA, Eby CS, Scott MG, Coyne DW (2010) Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78(8): 769-73.
13. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, et al. (2009) Timing of onset of CKD related metabolic complications. J Am Soc Nephrol 20(1): 164-71.
14. Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, et al. (2012) Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 7(1): 35-42.
15. Lipschitz DA, Cook JD, Finch CA (1992) A clinical evaluation of serum ferritin as an index of iron stores. Nutrition 8(6): 443-8.
16. Hintze KJ, McClung JP (2011) Hepcidin A Critical Regulator of Iron Metabolism during Hypoxia. Adv Hematol 2011; 510304.
17. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, et al. (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117(25): e218-25.
18. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, et al (2012) Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.; CONTRAST Investigators. PLoS One 7(7): e39783.
19. Valenti L, Messa P, Pelusi S, Campostrini N, Girelli D (2013) Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med 14: 1-7.
20. Pelusi S, Girelli D, Rametta R, Campostrini N, Alfieri C, et al (2013) The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol 14: 4.
21. Bekri S, Gual P, Anty R, Luciani N, Dahman M, et al. (2006) Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131(3): 788-96.
22. Bartnikas TB, Andrews NC, Fleming MD (2011) Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood 117(2): 630-7.
23. Gkouvatsos K, Papanikolaou G, Pantopoulos K (2012) Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 1820(3): 188-202.
24. Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, et al. (2014) NephroTest Study Group. A 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia. PLoS One 19; 9(2): e84144.
25. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, et al. (2009) Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4(6): 1051-6.
26. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF (2010) Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 25(3): 848-53.
27. Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, et al. (2012) Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 27(3): 1076-83.
28. Canavesi E, Alfieri C, Pelusi S, Valenti L (2012) Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol 1(6): 166-176.
29. Peters HP, Laarakkers CM, Pickkers P, Masereeuw R, Boerman OC, et al. (2013) Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol 14: 70.
30. Kim A, Fung E, Parikh SG, Valore EV, Gabayan V, et al. (2014) A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 123(8): 1129-36.